Life Sciences Archive » July, 2016

Life Sciences - July, 2016

330 articles

• WL Gore Can't Recover Lost Profits In Stent IP Row: Judge
• Celesio, Sainsbury's Pharmacy Deal Gets UK Approval
• Otsuka's 'Convoluted' Logic Spurned In Abilify Maintena Row
• Bausch & Lomb Eye Drop Patents Survive AIA Review
• NJ Merck Workers Suspend FLSA Suit Amid Settlement Talks
• Pair Admits To Illegal Money Moves After Meningitis Deaths
• United Healthcare Sues Cephalon Over Provigil Pay-For-Delay
• Product Liability Regulation & Legislation: Midyear Report
• EPA Won't Rethink Bayer's Challenge To Axed Pesticide
• Health Hires: Cooley, Lowenstein, Foley Grow Life Sci Teams
• Fed. Circ. Says PTAB Was Wrong To Uphold Zoll Patent
• IK Investment Partners Sells Dutch OTC Drug Co. Vemedia
• A 'Smoking Gun' In Reverse-Payment Settlements
• Shedding Further Light On The FCPA Pilot Program
• Merck Asks Supreme Court To Hear PTAB Deference Row
• Prevent Litigation From Becoming A Threat To Data Security
• PTAB Nixes 6 Jazz Pharma Patents In AIA Reviews By Rivals
• J&J Denied Bid For Speedy 5th Circ. Appeal In Hip MDL
• More Expert Testimony Allowed In 1st Tylenol Bellwether
• Bayer Beats 1,200 Suits Over Mirena IUD Injuries
• Millennium Fights $5M HIPAA Coverage Loss At 9th Circ.
• Judge Won't Change $70M Jury Verdict Against Neovasc
• SynCardia Creditors Worried Over DIP, Bidding Orders
• Deals Rumor Mill: Allegro, Zabka Polska, InVentiv Group
• DLA Piper Atty Wants Sanction, Contempt Order Lifted
• Medical Device Co. To Pay $11.5M Over Alleged Kickbacks
• Fosun To Buy KKR-Backed Indian Drug Co. For Up To $1.3B
• Pharma Co. Hit With Bias Suit From Ex-Global Study Leader
• Par Pharma Sued For Abusing Monopoly Of Vasopressin
• Corporations In The Crosshairs Of Product Liability Claims
• OPINION: Our Juries Are Being Circumvented
• Benicar MDL Partially Remanded To Missouri State Court
• Supplement Co. Loses Wash. Tax Liability Appeal
• Watson Pushes To Sever Lidoderm, Opana Pay-For-Delay Suits
• Democratic Leaders Want In On FDA's Theranos Probe
• Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit
• 3rd Circ. Won't Touch Avandia MDL Fee Ruling
• Bind Therapeutics Wins OK Of $40M Ch. 11 Sale to Pfizer
• High Court Lifts Stay On Merck Birth Control Patent Ruling
• Mylan Must Divest Two Generics To Buy Meda, FTC Says
• Bernstein Litowitz Rips Subpoena In Insider Trading Row
• FTC Clears Teva's $40.5B Generics Buy With Divestitures
• Colorado Pot Shop Fights IRS To Restore Tax Write-Offs
• Kadmon Prices IPO Below Range While Tactile Cuts Deal Size
• Deals Rumor Mill: Gland Pharma, SoundCloud, Xplornet
• Cost Of Wasted Eye Drops Counts As Harm, 3rd Circ. Told
• The Internet Of Health Things: Privacy And Security Issues
• Legal Aid, Meet Legal Tech
• 4 Traits Of The Top Litigation Firms
• 5 Small(er) But Mighty Litigation Shops
• Law360 Names Top 50 Firms For Litigation
• J&J Can't Speed Up Appeal In Hip MDL, Patients Tell 5th Circ.
• J&J Can't Nix Causation Experts In 1st Tylenol Bellwether
• Pa. Judge Won't Ax $70M Risperdal Breast-Growth Verdict
• FDA Updates Warnings For Antibiotics Class
• Drugmakers Say Rulings Don't Back Chicago Opioid Case
• Pharma Researcher Must Face Investor Suit Over Outage
• Deals Rumor Mill: Permira, Wako Pure Chemical, TransCanada
• Fed. Circ. Axes Illumina Bid To Arbitrate Ariosa Patent Row
• FDA Warning Wire: 'Slimy Build-Up' At Big Salad Co.
• Vertex Ignored Red Flags In Clinical Trial, 1st Circ. Told
• Arizona Ends 6-Year Freeze On CHIP Enrollments
• Mylan Wins PTAB Review Of Pfizer's Toviaz Patents
• Valeant, Par End Patent Suit Over Colitis Treatment
• Recent Off-Label Device Cases Are A Road Map For The Future
• Testing The UBE: Portable But Inaccurate Bar Exam Scores
• Couple Indicted After Meningitis Outbreak Want Charges Axed
• Eye Drop Dose Suit Against Allergan, Others Wins Class Cert.
• CVS' Vitamin E Actually Bad For Heart, 1st Circ. Told
• Brand Battles: Apple, Bristol-Myers, Novartis, Subway
• Consumers Fight Pfizer Bid To Escape Lipitor MDL
• Otsuka Asks 6th Circ. For Relief From Abilify FCA Suit
• CytRx Hit With Investor Suit Related To FDA Hold On Drug
• Paul Hastings Adds IP, Antitrust Pro From Patterson Belknap
• Merck Urges 9th Circ. To Reject Diabetes Drug Warning Claims
• FTC Fights To Preserve Gray Hair Supplement False Ad Suit
• Benefiting From FDA's Medical Device Risk-Benefit Guidance
• Teva, Forest Settle Patent Fight Over $759M Namenda XR
• Device Cos. Decry DOJ 'Smears' Amid Fraud Inquiry
• Ironshore Can't Escape 23andMe Test Accuracy Coverage Spat
• Can Reference Sponsor Forfeit Right To Sue Under BPCIA?
• Testing The UBE: Missouri Benefits From Uniform Bar Exam
• Minor Convictions In Acclarent Trial Raise Major Questions
• Taxation With Representation: MoFo, Davis Polk, Cooley
• NBTY Vitamins Falsely Labeled 'Made In USA,' Consumer Says
• CORRECTED: Medtronic IP Expert Dinged For Lack Of Mind-Reading Prowess
• Amgen's 'Pointless' Biosimilar Pathway Suit Gets Axed
• Drugmaker Can't Deny Contract, Then Sue Over It, Judge Told
• Roche Wins Appeal Of $18M Verdict In Accutane Suit
• High Court Stays Merck Birth Control Patent Ruling
• Calif. CVS Pharmacists Not Paid For Training, Suit Says
• NJ Man Gets 30 Mos. In $1M Corporate Embezzlement Scheme
• J&J Unit Settles Sinus-Device FCA Suit For $18M
• Anti-Zika Spray Will Hurt Citizens, Puerto Rico Mayor Says
• Generic Drug Price Surges Don't Always Point To Collusion
• J&J Unit Fails To Overturn $8M Hip Implant Verdict On Appeal
• Fed. Circ. Kills $20M AngioScore Win For Jurisdiction Flub
• Class Fee In $7.2B Receptos Merger Suit Slashed To $100K
• Foot Care Co. Can Appeal Trademark Verdict, Judge Rules
• AstraZeneca Sues Aurobindo For Nexium Patent Infringement
• Jones Day, Latham Guide Galenica's $1.5B Relypsa Buy
• Teva Sells Additional $5.4B In Bonds To Buy Allergan Unit
• Deals Rumor Mill: Shenhua Group, Engie, Fresenius
• Abbott Can't Put Depakote Blame On FDA, Mom Tells 6th Circ.
• Warner Chilcott, Zydus Face Leaner Product-Hop Suit
• Doc Accused Of Bribing Sen. Wants $2M Put In Fees Trust
• Boston Scientific Reaches $275M Settlement With IRS
• Dr. Reddy's Countersuit Rejected In Purple Pill Trademark Row
• PE-Backed Drug Services Firm, Tech Co. Net $692M In 2 IPOs
• Archer Daniels Faces Class Action Over Deadly Horse Feed
• Ethicon Says Professor Unfit To Testify In Pelvic Mesh MDL
• USPTO Cancer Drug Pilot Program Not Likely To Be Used Much
• Amgen To Pay $95M In Class Action Securities Settlement
• Mylan's Proposed Acquisition Of Meda Receives EU Approval
• Surgery Center Can't Trim Meningitis MDL, Tenn. Judge Told
• Fed. Circ. Revives Heart Rate Monitor Patent Row In Del.
• Endo Fluoride Labeling Suit Survives Dismissal Bid
• Diabetes Test Co. Says Jury Right To Deny $1M In Legal Fees
• 7th Circ. 'Pill Mill' Ruling Ushers In Nuisance Coverage
• Medical Supply Co. Wants Sanctions Over Patent Suit
• Celgene Paying Up To $2.6B In Jounce Cancer Collaboration
• Deals Rumor Mill: BC Partners, Mondelez, Clariant
• States Emboldened In Suboxone Antitrust Row After Namenda
• 5 States Clearing The Smoke On Pot Ethics Rules
• Ex-Acclarent Execs Beat Felony Off-Label Fraud Charges
• Merck Asks To Wait For Fed. Circ. In Gilead Atty Fees Row
• XY Urges Court To Consider Halo In Sex-Selection IP Case
• Pfizer Reaches Settlement In Drug-Risk Securities Suit
• AstraZeneca Loses Bid To Keep FDA OK From Generic Crestor
• Teva Settles Drug Patent Row With Celgene, Astellas
• Teva Sells $15B In Bonds To Help Fund Actavis Generics Deal
• Atty Must Give Law School Lectures As Punishment
• FDA Warning Wire: Penicillin Contamination And Cockroaches
• Deals Rumor Mill: Yahoo, Monsanto, Silver Run
• Ex-Morgan Stanley Broker Inks Sanofi Insider Trading Deal
• Stock Prices Aren't Enough For 'Rule Of Reason' Analysis
• Perrigo Investor Slams Co. Over Mylan's Failed Takeover
• Insurance Co. Must Defend 'Pill Mill' Suit, 7th Circ. Says
• Faulty Blood Test Suits Pile Up Against Theranos, Walgreens
• Ameritox Awarded $1.1M In Interest For Patent Case
• Fed. Circ. Clarifies Doctrine Of Equivalents In ANDA Litigation
• Monsanto Spurns Bayer's Sweetened Offer
• Icahn Urges 2nd Circ. To Affirm Toss Of Insider Trading Suit
• Warner Chilcott Can't Nix Pay-For-Delay Row: Loestrin Buyers
• Ex-Pharma Exec Wins Appeal To Not Arbitrate Wage Row
• Pa. Judge Won't Nix Tylenol Causation Study From MDL
• Eli Lilly Says Brazil Entity Covered In Contamination Row
• Feds Say NY Court Can't Rule On Pfizer's $8.3M Interest Row
• J&J Talcum Powder Suits Should All Go To Ill., JPML Told
• Applying Cartier V. BSkyB To UK Life Sciences Patents
• Fed. Circ. Denies Rehearing In Merck Patent Loss Case
• Skadden Steers Senior Housing Properties Trust's $620M Loan
• How Law Firms Can Create Next-Generation Office Spaces
• GlaxoSmithKline Denied Bid To Unpause Philly Paxil Litigation
• Feds Launch Internal Review Of Failed FedEx Criminal Case
• Retailers Say Birth-Control Drugmaker Stifled Generics
• Stunted-Chicken Ruling Hatches Fight Over Defect Exclusions
• USPTO Tells Examiners In Vitro Patent Ruling Clarifies Mayo
• Bayer Wants Dow Appeal Of $456M Crop Science Award Killed
• Health Hires: New Attys At PhRMA, Nelson Mullins, McDermott
• Ex-Acclarent Exec Takes Aim At FDA In Closing
• Generics Giant Teva Joins PhRMA, Shaking Up Brand Lobby
• NY Judge Looks To Trim Impax AIDS Drug Suit Against Turing
• Indivior Expects Product-Hopping Claims From 25 States, DC
• GSK, Indirect Purchasers Plan To Settle Pay-For-Delay Suit
• Smokers' Rights Groups Sue FDA Over New Tobacco Regs
• Taxation With Representation: Paul Weiss, Kirkland, Simpson
• PTAB Nixes Claims In Blue Belt Surgical Robotic Patent
• Deals Rumor Mill: Enbridge, Williams Cos., Walgreens
• Herbalife Seals $200M FTC Deal, Hires Davis Polk
• AbbVie Urges Judge To Nix FTC's Bid For 'Irrelevant' Info
• As Science Evolves, So Must Political Risk Insurance
• Halo Magnifies Patent Infringement Risks In M&A
• Why The Florida Supreme Court Shouldn't Undo Daubert
• Atty Sues Firms Over Share Of $30M Bristol-Myers Settlement
• Lipozene Class Cert. Process Should Go Forward, Court Told
• Tibet Pharma Investors Ask Court To Dismiss IPO Suits
• 3rd Circ. Free To Nix SEC Deal Post-Newman, Ex-Exec Says
• Jury Hears Rival Portraits Of Acclarent Execs In Fraud Trial
• Bayer Raises Buyout Offer To Entice Monsanto
• NJ Court Axes Insurer Win In Stunted-Chicken Coverage Fight
• Shkreli Wants To Sever Fraud Case From Ex-Kaye Scholer Atty
• Fed. Circ. Affirms Celgene Win In Bone Cancer Drug IP Case
• Deals Rumor Mill: Teva, Berkshire Hathaway, MBK Partners
• AbbVie's Biosimilar Criticisms 'Lack Merit,' FDA Says
• FTC Approves Invibio Monopoly Abuse Settlement
• An Update On Spoliation Sanctions Under Rule 37(e)
• FDA's Guidance On Medical Device Data Needs Improvement
• Pa. Cancer Center's Licensing Breach Claims Trimmed
• Texas AG Says Pharmacy Choice Rule Not Yet Enforceable
• J&J Asks 5th Circ. To Hurry Hip MDL Appeal
• Senate Passes Anti-Opioid Abuse Funding, Reform Bill
• Deals Rumor Mill: Jamieson Laboratories, Symantec, Carlyle
• Spectrum Settles Cancer Drug Patent Row With Fresenius
• Paul Hastings Scoops Up 2 Ropes & Gray IP Partners
• Travelers Denied Reconsideration Bid In $167M Coverage Row
• US Lawmakers Express Doping Enforcement Concerns To IOC
• Supplement Maker Slammed Over Allegedly Toxic Drink
• Seeger Weiss' Vioxx Deal Doesn't Bar Suit, 5th Circ. Told
• J&J Urges Pa. Judge To Nix $70M Risperdal Verdict
• Life Sciences Cases To Watch In The 2nd Half Of 2016
• AstraZeneca OKs Sandoz Cancer-Drug Generic For 2019
• Chicago Says Monster Energy Drink Ruling Backs Opioid Case
• Drug Cos. Say Lidoderm, Opana Pay-For-Delay Suit Improper
• FDA Overreaching With Tobacco Rule Expansion: E-Cig Cos.
• On Sale At Fed. Circ.: Clarity For Patent Invalidity Claims
• LabMD Draws Law Firms, Coke Into Tiversa Data Theft Row
• Anda Asks 11th Circ. To Return Coverage In 'Pill Mill' Case
• Sports Supplement Co.'s False Ad Suit Tossed
• GNC Says Investors Can't Back Up Illegal Drug Suit
• NJ Couple Must Pay $7.5M Judgment For Medicare Fraud
• BioArray Moves Rutgers IP Licensing Suit To Federal Court
• Jury Verdict Alone Enough For Willfulness Post-Halo: Judge
• Paragon BioTeck Blasts Eye Drop Supplier's Exec At PTAB
• Atty Tells 11th Circ. DOJ Cheated To Get His Fraud Conviction
• Impax Looks To Duck Endo's $100M Suit Over Drug Licensing
• Size Matters In Approving Pay-For-Delay Class, 3rd Circ. Told
• Lipozene Buyer Fights Maker's Bid To Toss False Ad Suit
• The Importance Of Adequate M&A Disclosures To Stockholders
• Valeant Unit Settles Sex Discrimination Claims For $7.2M
• Mylan Infringed Forest's Savella Drug Patents, Judge Rules
• PTAB Finds Becton's Remote Pharmacy Patent Obvious
• Gilead AIDS Drug Antitrust Case To Get Appeal
• P&G Seeks To Scrub Fixodent MDL After Experts Nixed
• Investors Accuse Stericycle Of Inflating Profits Through 'Fraud'
• Skyrocketing FCA Penalties Ripe For Constitutional Challenges
• Fed. Circ. Unfreezes Biotech Patents In CellzDirect
• OPINION: Stop Pharma Hopping Mischief
• Bard Says Jury Shouldn't Decide Triple Damages Bid In IP Suit
• Amgen Opens Trial In Fight Over Neulasta Generic
• Fed. Circ. Ruling Blunts On-Sale Bar's Threat To Patents
• Insurance Co. Says Testosterone Marketing Suit Must Stand
• Sandoz's Enbrel Biosimilar Gets FDA Staff Nod
• A Primer On Anda's 'Pill Mill' Coverage Battle With Travelers
• Federal Gov't Won't March In When It Comes To Drug Prices
• Lipocine Lied About Testosterone Pill's Chances, Investors Say
• Japanese Drug Co. To Pay $736M For US Generics Maker
• Boiron Says Jury Verdict Is Binding In False Ad Row
• How To Close A Law Firm — Practically And Ethically
• Anthem Slams Express Scripts Claims In $13B Pricing Row
• PE Firms Pay $3.55B For Thomson Reuters' IP, Science Unit
• Full Fed. Circ. Limits On-Sale Bar's Reach In Angiomax Case
• The First 90 Days Of DOJ's FCPA Pilot Program
• Becton Says New Evidence Justifies $167M Travelers Row
• Life Sciences Patents Boosted By Fed. Circ. Take On Mayo
• New States Fight Obama Transgender Policy, Big Biz Supports
• GSK Unit Pushes Back On SEC In Stock Fraud Suit
• Amgen's Humira Biosimilar Wins FDA Staff Support
• Acclarent Execs Ask Judge To Halt 'Confusing' Prosecution
• Buchanan Nabs Milbank Pharma, Import IP Pro
• Abbvie's Humira Patent Claims To Be Reviewed By PTAB
• FDA Offers Guidance For Updating Some Generic Labels
• Celator Reaches Deal In Suits Over $1.5B Sale To Jazz
• Merck Wants Genentech's Cancer Drug Patent Invalidated
• Celgene Tells Fed. Circ. Chemo IP Row Deserved Dismissal
• More Than 100 Plaintiffs Need New Attys In Zimmer MDL
• Boehringer Offers Fixes To Clear Sanofi Deal In EU
• After-Developed Defenses Still Relevant After Halo
• Illumina Settles DNA Patent Row With Enzo For $21M
• Taxation With Representation: Wachtell, Skadden, Orrick
• Limitations On Direct-To-Consumer Tests In Md. And NY
• Theranos CEO Holmes Gets 2-Year Lab Ownership Ban
• Atty Fees In Amerisource Shareholder Deal To Be Reworked
• St. Jude Ends Investor Suit Over Cardiac Devices For $39M
• Hospira, Amgen Duel Over Biosimilar Ruling's Impact
• FDA Cold On Freezing Treatments
• Medco Says Relator Brings Nothing New To FCA Case
• EU High Court Says Law Allows Royalties For Invalid Patents
• KaloBios Strips Ex-CEO Shkreli Of Shareholder Power
• Halo Saves $131M Verdict Against Cochlear, Fed. Circ. Told
• Evolving Insurance Coverage For Nanotechnology Risks
• The Smart Money Is Not Following Traditional Law Firms
• Bayer Admissions Can Carry IUD Claims, Consumers Say
• NJ Drug Co. Pleads Guilty To Gel Contamination Charges
• You Can't 'Patent Dance' Your Way Out Of Biosimilar Notice
• Medtronic Unit Pushes Fed. Circ. To Revive Spinal Implant IP
• GSK Denied Stay In Antitrust Suit Pending High Court Decision
• Gilead Beats Antitrust Suit Over HIV Drug Patents
• FDA Assails AstraZeneca's Attack On Crestor Generics
• Pfizer, Chicago Reach Opioid Marketing Pact
• SynCardia Pushes For Rapid Ch. 11 Sale Process
• Eli Lilly Escapes Cymbalta User's Withdrawal Class Action
• 9th Circ. Wipes Out 7-Year Medicare Fraud Sentence
• Ex-CEO Of Australian Pharma Co. Dodges Securities Suit
• Award In J&J Hip Implant Bellwether Trial Slashed To $150M
• Gilead Wants $15.5M In Fees From Merck After Hep C Upset
• Pharma Cos. Appeal Rejected Subpoena Of Express Scripts
• Hyland Can't Dodge Homeopathic False Ad Claims For Now
• Kirkland & Ellis Guides Ventas In $1.5B Real Estate Deal
• The High Court's Artificial And Fictitious Patent Test: Part 2
• RFP Lessons: 5 Ways Law Firms Can Beat Frustration
• After Verdict Reversal, Gilead Takes Aim At Merck Patents
• J&J, DePuy Can't Put Texas Hip Implant MDL On Hold
• SEC Seeks To Banish Ex-Pharma CEO After Fraud Verdict
• 7th Circ. Upholds Conviction For Unauthorized Drug Sales
• FDA Green Lights Abbott's Dissolving Coronary Stent
• Medivation In Talks With Sanofi After Rejecting Its $9.3B Offer
• Takeda Says USPTO Shorted Life Of Patent For Diabetes Drugs
• Jones Day Snags Latham & Watkins Life Sciences IP Pro
• FDA Warning Wire: Gluten, Rodents, Falsified Records
• Unsealed Lincare FCA Alleges Millions In Medicare Fraud
• Abbott Tells 6th Circ. Depakote Testimony Correctly Limited
• PTAB Wrong To Reject Flu Med IP, Fed. Circ. Hears
• Fed. Circ. Revives In Vitro's Cell Preservation Patent
• Pfizer Unit's Antibiotic Patent Faces Fed. Circ. Challenge
• FTC Says AbbVie Must Produce Board Docs In AndroGel Fight
• Deals Rumor Mill: Aetna, Marken, Iliad
• Chinese Pharma Firm Raises $150M From Private Investors
• Artificial Heart Maker Plans Quick Ch. 11 Sale Process
• Biosimilar Notice Always Mandatory, Fed. Circ. Rules
• The High Court's Artificial And Fictitious Patent Test: Part 1
• Kirkland Guides Bristol-Myers' $520M Cancer Drug Co. Buy
• RFP Lessons: 7 Tips To Improve Your Responses
• Inventor In Spinal Drug Row Asks Justices To Allow New Docs
• Quinn Emanuel To Bat For Elan Classes In SAC Trial
• Tyco Wants Attys' Fees After Win In $60M Drug Heist Suit
• Beleaguered Theranos' Bad Lab Tests Queried By Dems
• Health Hires: Greenberg, Covington Add IP, Deals Pros
• Consumers Eye Deal On Documents In Contact Lens MDL
• Justices Urged To Take Up FCA Row Over Bayer Anthrax Drug
• Dopamine Agonist Drugs Need Compulsion Warning: Group
• 1st Circ. Upholds Dismissal Of FCA Suit Against CVS
• Feds Blast Easing Of House Arrest For Exec Murder Suspect
• CPSC Chair Praises Industry Push For Window Blind Safety
• 2nd Circuit Affirms Tossing Mirena Claims Against Bayer
• Czechs Ask Full DC Circ. To Flip Panel's OK Of $325M Award
• KaloBios Emerges From Ch. 11 With Chagas Drug Rights
• J&J Unit Slammed With $70M Verdict In Philly Risperdal Trial
• Diagnosing The Sequenom Problem
• RFP Lessons: A General Counsel's List Of Law Firm Mistakes